Project Grant R01CA311885
Award Date 7/20/26
Completion Date 6/30/31
Dollars Obligated $697K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute's Cancer Biology Research program (CFDA 93.396) awarded $703,423 to Weill Medical College of Cornell University beginning June 1, 2026, through May 31, 2031. This Project Grant supports fundamental research to identify and validate therapeutic targets for mitigating immunotherapy-associated immune-related adverse events (IRAEs) while preserving anti-tumor immunity. The research uses skin IRAEs as a model system to elucidate...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Weill Medical College of Cornell University a $702,461 Project Grant effective June 1, 2026, through May 31, 2031, under the Cancer Cause and Prevention Research program (CFDA 93.393) to evaluate the impact of a novel educational intervention designed to improve timely colposcopy follow-up and treatment among high-risk populations. The award supports a hybrid type 1A implementation-effectiveness trial testing the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a $630,089 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective May 1, 2026, through April 30, 2031. This award funds research to characterize the molecular functions of SMARCAL1, a DNA translocase protein involved in regulating anti-tumor immune responses. The research addresses a critical gap in cancer immunotherapy by...
- Federal Grant Award Summary Weill Medical College of Cornell University received a $716,183 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective May 13, 2026, with a completion date of April 30, 2031. The award supports research to advance Chimeric Antigen Receptor (CAR) T-cell therapies by interrogating and targeting co-inhibitory and co-stimulatory molecules that limit current adoptive cell therapy effectiveness. The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Weill Medical College of Cornell University a $595,632 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective July 17, 2026, with completion anticipated by June 30, 2030. This research initiative employs a mixed-methods approach to optimize prostate cancer screening decision-making among older men by examining how screening cessation should be tailored to individual patient health...
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $435,243 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded July 1, 2026, with completion targeted for June 30, 2028. The award supports development and preclinical evaluation of GSK3 (glycogen synthase kinase 3) relocalizing peptides (R-PEPs) as a novel anti-cancer therapeutic approach. The research leverages the institution's platform...
- Federal Grant Award Summary Award Details: Weill Medical College of Cornell University received a $169,291 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) for the period May 1, 2026 through April 30, 2028. The award supports research titled "Characterizing the Cooperative Role of E2F1 and Interacting Proteins in Driving Advanced Prostate Cancer." Research Scope and Deliverables: The grant funds mechanistic...
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $204,027 project grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective August 1, 2025 through July 31, 2030. This award supports the development and application of advanced single-cell and spatial technologies designed to link clonal genotypes with phenotypes during cancer evolution. The project addresses a critical gap in cancer research by...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Weill Medical College of Cornell University a $2,013,199 Project Grant effective September 1, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award supports the expansion of NCI-sponsored clinical research in hematologic malignancies to Brooklyn and Queens through the Meyer Cancer Center (MCC) at Weill Cornell Medicine and NewYork-Presbyterian. The initiative addresses significant unmet cancer...
- Federal Project Grant Award Summary Funding Agency: National Cancer Institute (NCI) Federal Grant Program: Cancer Biology Research (CFDA 93.396) Award Amount: $697,131 Award Date: May 1, 2026 Project Completion Date: April 30, 2031 Awardee: Icahn School of Medicine at Mount Sinai, New York, NY This five-year Project Grant supports fundamental cancer biology research investigating the myeloid-stromal axis in colorectal cancer (CRC) immunosuppression and resistance to immune checkpoint blockade...